Trial: 202010115

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Phase

II

Principal Investigator

Lim, Kian-Huat

Disease Site

Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder

Learn more about this study at: clinicaltrials.gov